The majority of prostate cancer (Pca) patient morbidity can be attributed to bone metastatic events， which poses a significant clinical obstacle. Therefore， a better understanding of this phenomenon is imperative and might help to develop novel therapeutic strategies. Stromal cell-derived factor 1α (SDF-1α) and its receptor CXCR4 have been implicated as regulators of bone resorption and bone metastatic development， suggesting that agents able to suppress this signaling pathway may be used as pharmacological treatments. In this study we studied if two CXCR4 receptor antagonists， Plerixafor and CTE9908， may affect bone metastatic disease induced by Pca in preclinical experimental models
The majority of prostate cancer (Pca) patient morbidity can be attributed to bone metastatic events， which poses a significant clinical obstacle. Therefore， a better understanding of this phenomenon is imperative and might help to develop novel therapeutic strategies. Stromal cell-derived factor 1α (SDF-1α) and its receptor CXCR4 have been implicated as regulators of bone resorption and bone metastatic development， suggesting that agents able to suppress this signaling pathway may be used as pharmacological treatments. In this study we studied if two CXCR4 receptor antagonists， Plerixafor and CTE9908， may affect bone metastatic disease induced by Pca in preclinical experimental models
